1. Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma. Issue 6 (13th February 2017) Authors: Xu, XS; Yan, X; Puchalski, T; Lonial, S; Lokhorst, HM; Voorhees, PM; Plesner, T; Liu, K; Khan, I; Jansson, R; Ahmadi, T; Ruixo, JJ Perez; Zhou, H; Clemens, PL Journal: Clinical pharmacology & therapeutics Issue: Volume 101:Issue 6(2017) Page Start: 721 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Novel primary thymic defect with T lymphocytes expressing gamma delta T cell receptor. Issue 7 (July 1989) Authors: Geisler, C; Pallesen, G; Platz, P; Odum, N; Dickmeiss, E; Ryder, L P; Svejgaard, A; Plesner, T; Larsen, J K; Koch, C Journal: Journal of clinical pathology Issue: Volume 42:Issue 7(1989) Page Start: 705 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL. (5th April 2022) Authors: Dimopoulos, MA; Oriol, A; Nahi, H; San-Miguel, J; Bahlis, NJ; Usmani, SZ; Rabin, N; Orlowski, RZ; Suzuki, K; Plesner, T; Yoon, SS; Ben Yehuda, D; Richardson, PG; Goldschmidt, H; Reece, D; Ahmadi, T; Qin, X; Garvin Mayo, W; Gai, X; Carey, J Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗